The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Alan K Burnett; Nigel H Russell; Dominic Culligan; Jamie Cavanagh; Jonathan Kell; Keith Wheatley; Andra Virchis; Robert K Hills; Donald Milligan; AML Working Group of the UK National Cancer Research Institute

doi:10.1111/j.1365-2141.2012.09165.x

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Alan K Burnett, Nigel H Russell, Dominic Culligan, Jamie Cavanagh, Jonathan Kell, Keith Wheatley, Andra Virchis, Robert K Hills, Donald Milligan, AML Working Group of the UK National Cancer Research Institute

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

Original language	English
Pages (from-to)	519-22
Number of pages	4
Journal	British Journal of Haematology
Volume	158
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2141.2012.09165.x
Publication status	Published - Aug 2012

Bibliographical note

Access to Document

10.1111/j.1365-2141.2012.09165.x

Cite this

Burnett, A. K., Russell, N. H., Culligan, D., Cavanagh, J., Kell, J., Wheatley, K., Virchis, A., Hills, R. K., Milligan, D., & AML Working Group of the UK National Cancer Research Institute (2012). The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology, 158(4), 519-22. https://doi.org/10.1111/j.1365-2141.2012.09165.x

@article{50db8386392241a8a99c7dc56a634f00,

title = "The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML",

abstract = "The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.",

author = "Burnett, {Alan K} and Russell, {Nigel H} and Dominic Culligan and Jamie Cavanagh and Jonathan Kell and Keith Wheatley and Andra Virchis and Hills, {Robert K} and Donald Milligan and {AML Working Group of the UK National Cancer Research Institute}",

note = "{\textcopyright} 2012 Blackwell Publishing Ltd.",

year = "2012",

month = aug,

doi = "10.1111/j.1365-2141.2012.09165.x",

language = "English",

volume = "158",

pages = "519--22",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley",

number = "4",

}

Burnett, AK, Russell, NH, Culligan, D, Cavanagh, J, Kell, J, Wheatley, K, Virchis, A, Hills, RK, Milligan, D & AML Working Group of the UK National Cancer Research Institute 2012, 'The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML', British Journal of Haematology, vol. 158, no. 4, pp. 519-22. https://doi.org/10.1111/j.1365-2141.2012.09165.x

TY - JOUR

T1 - The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

AU - Burnett, Alan K

AU - Russell, Nigel H

AU - Culligan, Dominic

AU - Cavanagh, Jamie

AU - Kell, Jonathan

AU - Wheatley, Keith

AU - Virchis, Andra

AU - Hills, Robert K

AU - Milligan, Donald

AU - AML Working Group of the UK National Cancer Research Institute

PY - 2012/8

Y1 - 2012/8

N2 - The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

AB - The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

U2 - 10.1111/j.1365-2141.2012.09165.x

DO - 10.1111/j.1365-2141.2012.09165.x

M3 - Article

C2 - 22639959

SN - 1365-2141

VL - 158

SP - 519

EP - 522

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this